Add this topic to your myFT Digest for news straight to your inbox
AstraZeneca’s $39bn takeover of US bio group Alexion is a milestone moment in a busy year for M&A
For executives browsing DD, there are lessons to learn from the Pfizer/AstraZeneca saga
There comes a time when almost every leader starts to become complacent
Albert Bourla to take top job at US drugmaker from January next year
Ian Read’s decision to lift drug prices was a political misjudgment — and not his first
Pfizer faced presidential fire for its price rises but others use more subtle tactics
Ian Read benefited from Donald Trump before he crossed him
Unusual U-turn on 100 products including Viagra follows criticism from US president
Politics again thwarts chief executive Ian Read’s plans to reshape drugmaker
Industry executives welcome president’s vow as way to lower prices
US drugmaker concludes that division costs would be ‘value destructive’
World’s second-biggest pharmaceuticals company aims to become leading player in oncology
An FT analysis shows big pharma still makes billions from drugs after patents lapse
Ian Read says case for drugmaker’s break-up has become ‘more complicated’ in recent months
Drugmaker says part of business could be relocated overseas in possible break-up
Total value of abandoned deals this year at highest since eve of financial crisis
Obama administration’s proposal blocks Ian Read’s grand plan
International Edition